Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (10)

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

2022

  1. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  2. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2021

  1. Genetically determined telomere length and multiple myeloma risk and outcome

    Blood Cancer Journal, Vol. 11, Núm. 4

2020

  1. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma

    Blood Advances, Vol. 4, Núm. 23, pp. 6023-6033

2012

  1. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

    Leukemia, Vol. 26, Núm. 10, pp. 2159-2171

  2. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

    Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819

2010

  1. Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Blood, Vol. 116, Núm. 8

2007

  1. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

    Leukemia, Vol. 21, Núm. 2, pp. 201-206

2004

  1. Influence of biologic markers on the outcome of Hodgkin's lymphoma: A study by the Spanish Hodgkin's Lymphoma Study Group

    Journal of Clinical Oncology, Vol. 22, Núm. 9, pp. 1664-1673